Anelixis announces the conclusion of AT-1501 Phase 1 clinical trial
Category: #health  By Saipriya Iyer  Date: 2019-11-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Anelixis announces the conclusion of AT-1501 Phase 1 clinical trial

Anelixis Therapeutics has reportedly concluded its testing of an investigational antibody, AT-1501, in a Phase 1 clinical trial in healthy volunteers as well as eight patients suffering from amyotrophic lateral sclerosis (ALS). The company further announced that it has raised enough funds to advance to AT-1501’s Phase 2 clinical trial.

The Phase 1 trial came out with a positive result as AT-1501 was well-tolerated at every dose that was tested. The processing of the drug inside the body, which is also called pharmacokinetics, was the same as was predicted by the researchers. The details of the study are to be presented at scientific meetings expected held in the future.

The company anticipates this data to support more clinical studies regarding ALS as well as other disorders to further analyze the tolerability and safety of AT-1501, including other clinical parameters like potential biomarkers.

AT-1501 happens to be an investigational antibody targeting CD40 ligand (CD40L), which is essentially a kind of protein on the surface of white blood cells causing inflammation. The U.S. Food and Drug Administration has given this therapy the designation of an orphan drug. 

The ALS Therapy Development Institute (ALS TDI) has developed AT-1501 with the help of numerous ALS organizations such as ALS Finding a Cure, ALS Association and ALS ONE. The Phase 1 trial was funded by ALS Association by over $1 million.

CEO and Founder of Anelixis, Steven Perrin, Ph.D., stated that allograft rejection, autoimmune diseases and ALS represent large unmet medical needs and the company is looking forward to exploring AT-1501’s potential value as diligently and quickly as possible. Advancement of the drug into a strong clinical research program will be providing significant potential opportunities for all the patients both in the ALS and the diabetes communities, he added.

 

Source Credits- https://alsnewstoday.com/2019/11/21/anelixis-therapeutics-als-therapy-at-1501-phase-2-clinical-trial/



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Tetra Pak announces target to reach net-zero GHG emissions by 2030
Tetra Pak announces target to reach net-zero GHG emissions by 2030
By Saipriya Iyer

Tetra Pak, a food processing and packaging solutions provider, has recently announced its target to reach net-zero GHG (greenhouse gas) emissions in its operations by 2030.

The targ...

DTE Energy pledges to reach net-zero emissions of GHG by 2050
DTE Energy pledges to reach net-zero emissions of GHG by 2050
By Saipriya Iyer

DTE Energy has reportedly pledged to reach the net-zero GHG (greenhouse gas) emissions by 2050. This can be ensured through various actions involving customers, suppliers, and its infrastructure, that align with the lo...

Researchers investigate a novel treatment for Childhood Alzheimer’s
Researchers investigate a novel treatment for Childhood Alzheimer’s
By Saipriya Iyer

Researchers at the Lundquist Institute have reportedly collaborated with the Cure Sanfilippo Foundation on a new clinical trial to investigate if repurposing an anti-inflammatory drug could provide relief to children t...